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mone	 (ACTH)	 in	 stressed	 rodents.	 The	AVP gene encodes a propeptide precursor 
containing	AVP,	AVP-associated	neurophysin	II	(NPII),	and	a	glycopeptide	copeptin,	
although it is currently unclear whether copeptin is always cleaved from the neuro-
physin	and	whether	the	NPII	and/or	copeptin	have	any	functional	role	in	the	pituitary.	
Furthermore,	for	primates,	it	is	unknown	whether	CRF,	AVP,	NPII	and	copeptin	are	
all colocalised in neurosecretory vesicles in the terminal region of the paraventricular 
CRF	neurone	axons.	Therefore,	we	 investigated,	by	 fluorescence	and	 immunogold	
immunocytochemistry,	 the	 cellular	 and	 subcellular	 relationships	 of	 these	 peptides	
in	 the	 CRF-	 and	 AVP-producing	 cells	 in	 unstressed	 Japanese	 macaque	 monkeys	
(Macaca fuscata).	Reverse	transcription-polymerase	chain	reaction	analysis	showed	
the	expression	of	both	CRF	and	AVP	mRNAs	in	the	monkey	PVH.	As	expected,	 in	
the	 magnocellular	 neurones	 of	 the	 PVH	 and	 supraoptic	 nucleus,	 essentially	 no	






and	 copeptin	 immunoreactivity	 in	 dense-cored	 vesicles	 of	 CRF-containing	 axons.	
The	 results	are	consistent	with	an	 idea	 that	 the	AVP	propeptide	 is	processed	and	
NPII	and	copeptin	are	colocalised	in	hypothalamic-pituitary	CRF	axons	in	the	median	
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1  | INTRODUC TION
The hypothalamic neuroendocrine response to stress is an import-
ant	 survival	 mechanism	 in	 vertebrates.	 Corticotrophin-releasing	
factor	 (CRF),	 a	 41-amino-acid	 peptide,	 potently	 stimulates	 adre-
nocorticotrophic	 hormone	 (ACTH)	 secretion	 from	 the	 anterior	
pituitary when released into the portal capillaries of the median 
eminence	 (ME)	 from	 terminals	 of	 parvocellular	 neurones	 of	 the	
hypothalamic	paraventricular	nucleus	(PVH).1-3 The release of ar-





including rats11 and humans.12	 Furthermore,	 the	 expression	 of	
the	AVP	gene	 in	CRF	neurones	 is	 increased	under	 stressed	con-
ditions.13,14 Translation of the AVP gene results in the formation 
of	a	propeptide	which	is	cleaved	to	release	the	AVP	hormone,	but	
which	also	contains	 the	AVP-associated	neurophysin	 (NP)	 II,	and	
a glycopeptide copeptin.15-17	The	NPII	has	the	important	function	
of	binding/stabilising	the	AVP,18 although the function of the co-
peptin	and	when	and	if	it	is	proteolytically	cleaved	from	the	NPII	is	
currently unclear.19	In	many	mammals,	including	rats	and	humans,	
ultrastructural	 immunocytochemistry	 demonstrates	 that	 CRF	
and	AVP	are	co-packaged	 into	 the	same	neurosecretory	vesicles	
(NSVs)	in	the	CRF-positive	(+)	and	AVP+ subpopulation of fibres in 
the	ME,	indicating	that	they	are	almost	certainly	co-released	into	
the portal capillary blood.20,21	 The	 concentration	 of	 AVP	 in	 the	
pituitary portal vessels increases when animals are stressed or are 
subjected to adrenalectomy.22	Although,	in	unstressed	mice,	very	
few	parvocellular	neurones	are	doubly	positive	for	CRF	and	AVP,	
severe stress or adrenalectomy significantly increases the ratio of 




evidence for the function of the secreted copeptin is currently 
lacking.19 The present study provides the first evidence in the hy-
pothalamus	 of	 unstressed	 Japanese	 macaque	 monkeys	 (Macaca 
fuscata)	that	CRF,	AVP,	and	the	AVP-associated	NPII	and	copeptin	
are	all	co-packaged	within	the	NSVs,	and	therefore	that	the	AVP	
precursor protein undergoes proteolysis during the passage of 
NSVs	from	the	CRH	perikarya	to	the	ME.
2  | MATERIAL S AND METHODS
2.1 | Animals






able	 ad	 lib.	All	 animals	were	kept	 in	 individual	 cages.	The	housing	
and	experimental	protocols	followed	the	guidelines	of	the	Ministry	
of	Education,	Culture,	Sports,	 Science,	 and	Technology	 (MEXT)	of	
Japan,	 and	 were	 in	 accordance	 with	 the	 Guide	 for	 the	 Care	 and	
Use	 of	 Laboratory	 Animals	 prepared	 by	 Okayama	 University,	 by	
Kyoto	 Prefectural	 University	 of	Medicine,	 and	 by	 Kansai	Medical	
University.	All	efforts	were	made	to	minimise	animal	suffering	and	
reduce the number of animals used in the study.
2.2 | Experimental procedures
2.2.1 | RNA extraction and reverse transcription-
polymerase chain reaction (RT-PCR)
One male and two female monkeys were anaesthetised with an over-
dose	of	sodium	pentobarbital	(50-90	mg	kg–1	body	weight),	transcar-
dially	 perfused	with	 physiological	 saline,	 and	 killed	 via	 blood	 loss.	
The	hypothalamus	and	cerebral	cortex	(temporal	lobe)	were	quickly	
removed	 and	 frozen	with	 powdered	dry	 ice	 and	 stored	 at	 −	80ºC	






with the manufacturer's instructions. The concentration of total 
RNA	was	measured	using	a	NanoDrop	Lite	(Thermo	Fisher	Scientific,	
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2%	agarose	gels.	RT-PCR	studies	were	 repeated	 three	 times	using	
independently	 extracted	 RNA	 samples	 from	 different	 animals.	
Consistent results were obtained from each run.
2.2.2 | Tissue preparation for microscopic analysis
Two male and two female monkeys were anaesthetised with an 
overdose	 of	 sodium	 pentobarbital	 (50-90	 mg	 kg–1	 body	 weight),	
and transcardially perfused with physiological saline followed by 
4%	 paraformaldehyde	 (PFA)	 in	 0.1	m	 phosphate	 buffer	 (pH	 7.4).	
Hypothalami were immediately removed and immersed in either 
4%	PFA	 in	0.1	mol	 L-1	 phosphate	buffer	 (for	 immunofluorescence)	
or	4%	PFA	+	0.1%	glutaraldehyde	(for	electron	microscopic	studies)	
for	16-24	hours	at	4ºC.	The	fixed	tissue	was	then	sectioned	in	the	




taining	 0.3%	Triton	X-100	 (PBST)	 three	 times	 for	 5	minutes	 each.	
After	blocking	nonspecific	binding	with	1%	normal	goat	serum	and	
1%	 bovine	 serum	 albumin	 (BSA)	 in	 PBST	 for	 30	minutes	 at	 room	
temperature,	 the	 sections	were	 incubated	with	primary	 rabbit	 an-
tisera	directed	against	CRF	(dilution	1:20	000)	or	copeptin	(dilution	
1:10	 000)	 and	 with	 a	 mouse	 monoclonal	 anti-AVP-NPII	 antibody	
(dilution	1:1000)	for	4-5	days	at	4ºC.	The	rabbit	polyclonal	antise-
rum	 against	 rat/human	 copeptin,	which	was	 generated	 by	 us,	 has	
been characterised previously via western analysis in rats.24 The 
copeptin7-14	(ATQLDGPA)	fragment,	used	as	an	antigen	to	produce	
our	copeptin	antiserum,	 is	well	conserved	 in	mammals.	 It	 is	 identi-
cal	 in	 rats,25	mice,26	macaque	monkeys	 (GenBank	 accession	 num-
bers	 XM_005568487.2	 [M. fascicularis]	 and	 XM_011741311.2	 [M. 
nemestrina]),	 common	 marmosets	 (GenBank	 accession	 number	
XM_002747402.2	[Callithrix jacchus])	and	humans.25	Thus,	our	anti-




which	 was	 kindly	 donated	 by	Wylie	 Vale,	 has	 been	 characterised	
elsewhere.29	 It	was	directed	against	 the	 rat	 form	of	CRF,	which	 is	
identical	 to	 the	 human	 form,	 and	 has	 also	 been	 characterised	 in	
non-human	primates.30	Alexa	Fluor	546-linked	anti-mouse	immuno-
globulin	G	 (IgG)	 (Molecular	Probes,	Carlsbad,	CA,	USA)	 and	Alexa	
Fluor	488-linked	anti-rabbit	 IgG	 (Molecular	Probes)	were	used	 for	
detection at 1:1000 dilution. Immunostained sections were viewed 




thick	 PVH	 sections	 per	 animal	 (n	=	 4	monkeys;	 two	 females,	 two	
males),	we	analysed,	at	200×	magnification,	unit	areas	 (630	× 630 
μm2)	in	the	PVH	containing	CRF-positive	neurones.	In	total,	87	unit	
areas from 17 sections were analysed. The number of the immunore-
active cells with clearly visible transected nuclei was counted.
The	 co-expression	 ratio	 of	 the	 immunoreactivity	 for	CRF/NPII	
was	 also	 determined	 in	 sections	 of	 the	ME.	 For	 each	 of	 the	 four	
to	 five	 30-µm	 thick	 sections	 per	 animal	 (n	= 4 monkeys; two fe-
males,	 two	males),	we	 analysed	 at	 400×	magnification,	 unit	 areas	
(50	× 50 μm2)	to	determine	CRF/NPII	immunoreactivity.	In	total,	74	
unit	areas	in	the	external	layer	and	60	unit	areas	in	the	internal	layer	
from 17 sections were analysed. The optical density of the immunos-
taining	of	CRF	(green),	NPII	(magenta)	and	the	merged	images	(green,	
magenta	 and	white)	were	 all	 determined	by	preparing	black-white	
images that were converted from each immunofluorescence micro-
graph	 using	 ImageJ,	 version	 1.52a	 (National	 Institutes	 of	 Health,	
Bethesda,	MD,	USA).	The	optical	density	of	the	background	labelling	
was estimated by comparison with similar areas of the control sec-
tions	(see	Supporting	information,	Figure	S1).	Each	threshold	optical	
density was determined by normalising the data to those of the con-
trol	sections.	The	CRF/NPII-immunoreactive-fibre	pixel	density	was	





TA B L E  1   Primary antibodies used in the present study
Antigen Description
Source, host species, cat#, 
or code# Working dilution
Reference 
number RRID



































coated	with	 (or	without	 for	 triple	 labelling)	a	collodion	film,	 rinsed	
with	PBS	several	times,	then	incubated	with	2%	normal	goat	serum	
and	 2%	 BSA	 in	 50	 mmol	 L-1	 Tris(hydroxymethyl)-aminomethane-
buffered	saline	(pH	8.2)	for	30	minutes	to	block	nonspecific	binding.	











NPII	 and	 copeptin	was	 performed	 by	 using	 the	 front	 and	 back	 of	





primary	 rabbit	 antibody	 (against	 copeptin)	 was	 performed	 on	 the	





shown in Table 1.
Quantification	 of	 labelled	 NSVs	 in	 the	 different	 varicosities	
was	 performed.	 At	 least	 five	 electron	 microphotographs	 (photo-
graphed at 5000× magnification; 3.6 × 3.6 µm2)	per	animal	 (n	= 4 
monkeys;	two	males	and	two	females)	of	randomised	regions	in	the	
external	 layer	of	 the	ME	were	analysed.	The	external	 layer	of	 the	
ME	was	defined	by	 the	diameter	of	NSVs	 (approximately	100	nm)	
as	 expected	 for	 axons	derived	 from	parvocellular	 neurones	 in	 the	
PVH.28,31	Labelled	NSVs	were	counted	manually	in	immunoreactive	
varicosities	 including	 three	 or	 more	 NSVs.	 Numbers	 of	 CRF-	 and	









The data are presented as the mean ±	SEM	and	were	analysed	using	
Statcel4	(version	4,	OMS	publishing,	Tokyo,	Japan).	Statistical	analy-
sis	of	 the	number	of	CRF-	and	NPII-specific	gold	particles	was	as-
sessed via Student's t test.
3  | RESULTS
The	expressions	of	CRF,	AVP and OXT	mRNAs	in	the	PVH	were	ex-
amined	by	RT-PCR.	The	Supporting	 information	 (Figure	S1)	 shows	
that	 bands	were	detected	 at	 the	 expected	 sizes	 for	CRF,	AVP and 
OXT	genes	in	the	PVH	of	both	sexes.	CRF	mRNA	but	not	AVP or OXT 
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mRNAs	were	also	detected	in	the	cerebral	cortex.	Almost	equivalent	
amounts of GAPDH	 cDNA	were	 amplified	 from	RNA	preparations	
among	these	tissues,	which	showed	that	no	significant	RNA	degra-
dation had occurred and a proper RT was obtained in the present 
study.
Figure	 1	 shows	 the	 topographic	 distribution	 of	 the	 neuro-
nal	 components	 of	 the	 PVH,	 supraoptic	 nucleus,	 and	ME	 derived	







karya appeared to be of similar size. In the magnocellular part of the 
PVH	(PaM),	essentially	no	CRF	immunoreactivity	could	be	detected	
in	the	AVP(NPII)-immunoreactive	neurones	(Figure	2A;	arrows).	By	
contrast,	 in	 the	medial	 parvocellular	 part	 of	 the	 PVH	 (PaPV),	 nu-
merous	 neurones	 were	 CRF-immunoreactive	 and	 39.0	±	 0.6%	 of	
the	 CRF+	 perikarya	 contained	 detectable	 AVP(NPII)	 immunoreac-
tivity	 (Figure	 2B;	 arrows).	 Virtually	 all	 AVP(NPII)-immunoreactive	
neurones	 in	 the	 PVH	 also	 contained	 copeptin	 immunoreactivity	
(Figure	3).	The	CRF+	and	AVP(NPII)+ neurones were also more inter-
mingled with magnocellular neurones in the monkey than in rodent 
PVH,	 as	 reported	previously.30,32	 In	 the	 SON,	 no	neurones	 exhib-
ited	both	AVP(NPII)	and	CRF	 immunoreactivity	 (Figure	1).	The	 im-
munofluorescence	labelling	for	CRF	and	AVP(NPII)	 in	the	macaque	
ME	 shows	 the	 topographic	 distribution	 of	 the	 specific	 staining	 as	
reported	previously	(Figure	4).33,34	The	internal	and	external	zones	
were separated by a region in which the numerical density of immu-
noreactive	processes	was	much	 lower	 (Figures	4	and	5A).	A	dense	
plexus	of	CRF+	fibres	was	present	in	the	external	layer	of	the	ME	as	
reported	previously,33 and analysis of the immunoreactivity suggests 
that 52.3 ±	1.5%	of	CRF+	fibres	co-expressed	AVP(NPII)	(Figure	5A,	
arrowheads).	By	contrast,	in	the	internal	layer	of	the	ME,	AVP(NPII)+ 
fibres	were	 the	most	 prominent,	 and	 only	 2.8	±	 0.3%	 fibres	 con-
tained	 both	 AVP(NPII)	 and	 CRF	 immunoreactivity	 (Figure	 5A).	
Controls in which the primary antiserum was omitted showed no 
immunostaining	in	the	ME	(see	Supporting	information,	Figure	S1).	
Double-immunofluorescence	for	AVP(NPII)	and	the	AVP-associated	
copeptin	 showed	 that,	 as	 expected,	most	AVP(NPII)+ fibres in the 









Double-immunoelectron	 microscopy	 for	 CRF/AVP(NPII)	 (Figure	 6)	
showed	 that,	 in	 the	 varicosities	 where	 both	 immunoreactivity	 was	


















indicate perikarya doubly immunopositive 
for	CRF	and	AVP(NPII)	in	the	PaPV.	Scale	














the	percentage	for	those	containing	only	AVP(NPII)+ was 0.6 ±	0.4%.	







nopositive	vesicles	were	 frequently	 seen.	Neighbouring	 fibres	often	
contained	 only	 CRF	 single-positive	NSVs	 (Figure	 8A,	 asterisk,	 C,C').	
Very	few	gold	particles	were	associated	with	other	intra-varicosity	or-
ganelles,	such	as	the	mitochondria,	and	background	labelling	over	glial	
and	 endothelial	 elements	 was	 also	 extremely	 low.	 Immunoelectron	
microscopy studies were repeated independently at least three times 




F I G U R E  3  Double-label	


















F I G U R E  4  Low	magnification	images	of	macaque	median	eminence.	Double-label	immunofluorescence	for	corticotrophin-releasing	
factor	(CRF)	and	vasopressin	(AVP)-associated	neurophysin	(NPII)	in	the	median	eminence	shows	topographic	distribution	of	the	
immunoidentified	peptides	as	previously	reported.	Immunoreactivity	against	CRF	(green)	and	AVP(NPII)	(magenta)	is	merged	on	the	right	
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parvocellular neurones in the rat20	 and	mouse,23 as well as in the 
human	PVH.12,21,35	However,	although	it	appears	likely	that	CRF	and	
the	 other	 AVP	 precursor	 components	 (NPII	 and	 copeptin)	 are	 co-
packaged	within	the	same	NSV	in	the	primate	hypothalamus,	there	
has thus far been no anatomical evidence.
In	our	unstressed	monkeys,	in	the	medial	part	of	the	PVH	where	
the	 parvocellular	 perikarya	 from	 which	 axons	 project	 directly	 to	
the	ME	are	 located,	approximately	61%	of	CRF+ perikarya did not 
contain	 immunodetectable	 amounts	 of	NPII	 or	 copeptin	 (approxi-
mately	39%	contained	 immunodetectable	NPII).	 The	 internal	 zone	
of	 the	ME	 contained	 only	 a	 few	 CRF+	 fibres	 as	 expected.	 In	 the	
pre-terminal	region	between	the	internal	and	external	zones	of	the	
ME,	 only	 a	 minority	 of	 the	 CRF-immunoreactive	 fibres	 contained	
AVP(NPII)	 or	 copeptin	 immunoreactivity	 and	 the	 overall	 amount	
of	 immunoreactivity	was	 less	marked,	 suggesting	 that	 there	were	








cursor,	 although	 that	 either	 stress	 or	 adrenalectomy	 activates	 the	
production	of	AVP	 (and	 therefore	 the	AVP	precursor	molecule)	 in	
the	CRF	neurones.20,23 Our findings suggest that the difference in 
the	extent	to	which	AVP,	NPII	and	copeptin	are	present	in	the	CRF	




posterior	 pituitary,	 the	AVP	precursor	 has	 clearly	 been	 processed	
sufficiently	to	reveal	prominent	AVP(NPII)	and	copeptin	immunore-
activity in almost all of the fibres.
Both	magnocellular	 AVP	 and	 parvocellular	 CRF/AVP	 neurones	
express	the	prohormone	convertases,	PC1	and	PC2	in	rodents.36,37 
In	CRF/AVP	neurones,	the	expression	of	PC1	is	selectively	regulated	
by	 glucocorticoids,	 although	 adrenalectomy	 has	 no	 effect	 on	 PC1	






In	monkeys,	 the	 axons	 of	magnocellular	 AVP	 neurones	 proj-
ect	 to	 the	 posterior	 pituitary	 via	 the	 internal	 zone	 of	 the	 ME,	
whereas	other	AVP-producing	parvocellular	neurones	of	the	PVH	
have	 axons	 that	 project	 throughout	 the	 brain	 including	 the	 ex-




as a result of both adrenalectomy and stress.42 In the unstressed 
rat	ME,	approximately	44%	of	the	CRF-immunoreactive	axons	and	
terminals	were	stained	 for	AVP.	By	contrast,	 in	 the	adrenalecto-
mised	 rat	 ME,	 almost	 all	 of	 the	 CRF-immunoreactive	 terminals	
showed	 strong	 staining	 for	 AVP,	 suggesting	 that	 adrenalectomy	
causes	the	transformation	of	a	subpopulation	of	CRF+/AVP–	axons	










indicate tissue doubly immunopositive 
for	CRF	or	copeptin	and	AVP(NPII).	InL,	
internal layer of the median eminence; 
ExL,	external	layer	of	the	median	
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and	terminals	to	ones	which	are	CRF+/AVP+.20 Our results indicate 
that,	 as	 in	 rodents,20	 approximately	half	of	 the	CRF	neurones	 in	
monkeys maintained under unstressed conditions also produce 





is	unsurprising	that,	in	many	CRF	neurones,	the	AVP gene was not 
expressed	to	a	detectable	extent.
In	the	magnocellular	system,	any	clear	evidence	for	a	function	
of secreted copeptin is currently lacking.19	However,	experiments	
seeking	 a	 possible	 physiological	 role	 for	 either	NPII	 or	 copeptin	
have so far been confined to the systemic circulation and a poten-
tial	role	for	either	NPII	or	copeptin	in	the	anterior	pituitary	has	yet	
to	be	 investigated.	Our	 results	demonstrate	 that	CRF,	AVP(NPII)	








Schematic representations of the location of gold particles and 
neurosecretory	vesicles	are	shown	in	(B')	and	(C'),	respectively.	m,	
mitochondrion. Scale bars =	200	nm	in	(A)	and	100	nm	in	(C')
AVP(NPII)     : 15 nm gold









F I G U R E  7   Double immunoelectron microscopy for vasopressin 
(AVP)-neurophysin	(NPII)	and	copeptin	in	the	external	zone	of	the	
macaque	median	eminence.	Numerous	neurosecretory	vesicles	





Schematic representations of the location of gold particles and 
neurosecretory	vesicles	are	shown	in	(B')	and	(C'),	respectively.	m,	
mitochondrion. Scale bars =	200	nm	in	(A)	and	100	nm	in	(C')
AVP(NPII)     : 15 nm gold
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and copeptin can all be colocalised within neurosecretory ves-
icles	 in	 the	 hypothalamic	CRF-secreting	 system.	Copeptin	might	
therefore	 play	 a	 role	 in	 the	 hypothalamic-pituitary	 adrenal	 axis,	
although further studies is needed to demonstrate any such role.
In	conclusion,	immunofluorescence	and	post-embedding	multiple	
immunoelectron microscopy revealed the subcellular colocalisation 
of	CRF,	AVP-associated	NPII	and	copeptin	in	neurosecretory	vesicles	
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